Insulin Degludec and Insulin Aspart

Phase 3Small molecule

Insulin Degludec and Insulin Aspart is one of 56 small molecule programs targeting Type 2 Diabetes. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Type 2 DiabetesActive, not recruiting

CirrhosisActive, not recruiting

Type 2 DiabetesPhase 3

Active, not recruiting

CirrhosisPhase 3

Active, not recruiting

Competition

Competitive Landscape

885 competitors in Type 2 Diabetes

#DrugCompanyPhaseTrials

Byetta

AstraZeneca

Preclinical

55 2

Insulin Degludec and Insulin Aspart

Sunshine Lake Pharma Co., Ltd.

Phase 3

2 3

NOVOLIN R

Novo Nordisk

Preclinical

5 4

Cysteine Hydrochloride

Novartis

Preclinical

1 5

Pravachol

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

1 6

Lovaza

AstraZeneca

Preclinical

1 7

GLP-1

RRigshospitalet, Denmark

Preclinical

1 8

Blank Control

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Preclinical

1 9

Antiplatelet Drug

FFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Preclinical

1 10

Biasp 30

Novo Nordisk

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Post-ApprovalNot yet recruiting

Type 2 Diabetes

NCT07173712

Clinical

Trials by Indication[1]

Type 2 Diabetes2 trials

A Study of Insulin Degludec/Insulin Aspart Biosimilar (22011) Compared With Insulin Degludec/Insulin Aspart(Ryzodeg) in Participants With Type 2 Diabetes in China

Unknown status· Sunshine Lake Pharma Co., Ltd. logo

Sunshine Lake Pharma Co., Ltd.·Phase 3·NCT05802862·408 enrolled

Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes

Not yet recruiting·YYanbing Li·Phase 4·NCT07173712·324 enrolled

Cirrhosis1 trial

Research on Optimal Strategy of Hypoglycemic Therapy for Cirrhosis With Diabetes

Unknown status·HHuashan Hospital·Phase 3·NCT05641337·184 enrolled

Safety and Efficacy1 trial

Safety and Efficacy of Insulin Degludec/Insulin Aspart in Patients With T2DM

Completed·—·N/A·NCT05417841·218 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Insulin Degludec and Insulin Aspart. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Insulin Degludec and Insulin Aspart compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Insulin Degludec and Insulin Aspart. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sunshine Lake Pharma Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Sunshine Lake Pharma Co., Ltd.

Insulin Degludec and Insulin Aspart

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Type 2 Diabetes2 trials

Cirrhosis1 trial

Safety and Efficacy1 trial

References

Drug Info

Quick Facts

Related News